Open AccessFetal Bovine Serum Substitute: Implication for Their Use in Translating Adipose-Derived Stem Cells from Bench to Bedside (Review)
Author(s) -
Fonny Josh,
Hiroshi Mizuno
Publication year - 1970
Publication title -
jurnal plastik rekonstruksi
Language(s) - English
Resource type - Journals
eISSN - 2089-9734
pISSN - 2089-6492
DOI - 10.14228/jpr.v1i5.107
Subject(s) - fetal bovine serum , platelet lysate , umbilical cord , stem cell , adipose tissue , medicine , clinical trial , immunology , andrology , cell , chemistry , biology , platelet , biochemistry , microbiology and biotechnology
Recently, cell based therapy become a popular topic in research fields. This therapy offers great potential to treat many diseases. Adipose-derived stem cell (ASCs) is known to have the special characteristic due to its abundant availability and easily harvesting. Then it rapidly advanced into clinical trials for treatment of a broad range of medical conditions. Before translating ASCs from bench to bedside, this process is facing other problems through fetal bovine serum (FBS) elimination. Animal-derived serum is not a suitable option for ASCs expansion regarding the possibility of viral or bacterial infection and immune reaction. By replacing FBS with other non-animal serum which gives the same effect as FBS, may significantly enhances the safety and quality of ASCs. Pooled human AB serum (AB-HS), human serum (HS), pooled human plasma lysate (PL), umbilical cord serum (UCS)/placental serum (PS), thrombinactivated platelet rich plasma (tPRP) or serum free (SF)/xeno-free (XF) have been considered as FBS alternatives and some already applied in clinical trials with human cells. This article focuses on a prospective alternatives serum through the elimination of FBS.